Company: RGBP
Filing Date: 2025-05-16
Form Type: 10-Q
Source: 0001641172-25-011206
Chunk: 17

Company: Regen BioPharma Inc
Filing Date: 2025-05-16
Form: 10-Q
Item: Part I, Item 1
Chunk 17
---
 of Regen Biopharma, Inc. Series A Preferred Stock owned as of the Record Date, every one share of Series AA Preferred
Stock owned as of the Record Date, every one share of Series M Preferred Stock owned as of the Record Date and every one share of Series
NC Preferred Stock owned as of the Record Date.

On November 1, 202415,426,385share
of Common Stock were issued as a dividend to the Shareholders of record date of October 17. 2024 a dividend consisting of one share of
the Company’s common stock for every one share held as of October 17, 2024. 15,426,385common shares were paid to Shareholders
of Record.

On November 4, 2024 the Company issued500,000shares
of the Company’s common stock in satisfaction of $20,000of principal convertible indebtedness.

On November 13, 2024 the Company issued370,084shares
of the Company’s common stock as consideration for nonemployee services

10. RELATED PARTY TRANSACTIONS

On June 23, 2015 the Company entered into an agreement
(“ Agreement”) with Zander Therapeutics, Inc. (“ Zander”) whereby The Company granted to Zander an exclusive worldwide
right and license for the development and commercialization of certain intellectual property controlled by The Company (“ License
IP”) for non-human veterinary therapeutic use for a term of fifteen years. Zander is under common control with the Company.

Pursuant to the Agreement, Zander shall pay to The
Company one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which must
be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on July 15th,
2016 and each subsequent anniversary of the effective date of the Agreement.

The abovementioned payments may be made, at Zander’s
discretion, in cash or newly issued common stock of Zander.

Pursuant to the Agreement, Zander shall pay to The
Company royalties equal to four percent (4%) of the Net Sales, as such term is defined in the Agreement, of any Licensed Products, as
such term is defined in the Agreement, in a Quarter.

Pursuant to the Agreement, Zander will pay The Company
ten percent (10%) of all consideration (